Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Bilayer Therapeutics logo — Developing innovative treatments for GI disease and metaboli...

Bilayer Therapeutics

Developing innovative treatments for GI disease and metabolic disorders (obesity & diabetes) based on GLP-1 and TGR5

Founded 2020 United States Cambridge, United States 1 employees Venture round Total: $2.00M Biotechnology, Health Care +2

General Information

Company Name Bilayer Therapeutics
Founded Year 2020
Location United States Cambridge, United States
Founders / Decision Makers
Team member
Employees 1
Industries Biotechnology, Health Care, Health and Wellness +1
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with Bilayer Therapeutics. To contact Bilayer Therapeutics, visit bilayer-therapeutics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Bilayer Therapeutics compare?

A PDF of Bilayer Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Bilayer Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Bilayer Therapeutics

Bilayer Therapeutics is a development-stage company focused on pioneering treatments for gastrointestinal (GI) disease and metabolic disorders such as obesity and diabetes. The company's approach utilizes GLP-1 and TGR5 - regulatory mechanisms for metabolism and motility. Founded in 2020 by a team of renowned drug development and delivery experts and gastroenterologists, Bilayer Therapeutics leverages a proprietary bilayer tablet technology to deliver chenodeoxycholate, a naturally occurring bile acid, to achieve its desired effects.

The company's innovative drug candidates, including BL-050 for metabolic disorder and BL-010 for motility disorders such as chronic constipation, aim to address unmet medical needs. Recently, Bilayer Therapeutics secured a $2.00M Venture Round investment on 28 April 2021, with Kendall Capital Partners participating as the investors.

Bilayer Therapeutics operates within the biotechnology, health care, health and wellness, and life sciences industries, with its headquarters based in the United States.

Business keywords: GI disease, metabolic disorders, obesity, diabetes, GLP-1, TGR5, bilayer tablet technology, drug development, bile acid, motility disorders, chronic constipation, innovative treatments, first-in-class treatments, drug candidate

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $2.00M 1
Kendall Capital Partners
Kendall Capital Partners
28 Apr 2021

Bilayer Therapeutics Alternatives & Competitors

View All Alternatives
Bilayer Therapeutics vs
Movetis NV
Movetis NV

See website

Series A
6 employees
Biotechnology, Health Care
Bilayer Therapeutics vs
Intercept Pharmaceuticals
Intercept Pharmaceuticals United States

Our mission is to build a healthier tomorrow for patients with rare and serious liver diseases.

Post-IPO Debt
376 employees
Biotechnology, Health Care
Bilayer Therapeutics vs
Xeno Biosciences
Xeno Biosciences United States

Gastric Bypass in a Pill

Series A
3 employees
Biotechnology, Health Care
Also compare with: Bilayer Therapeutics vs Allena Pharmaceuticals, Inc. Allena Pharmaceuticals, Inc. View all alternatives

FAQ About Bilayer Therapeutics

Developing innovative treatments for GI disease and metabolic disorders (obesity & diabetes) based on GLP-1 and TGR5
Bilayer Therapeutics was founded in 2020.
Bilayer Therapeutics is headquartered in Cambridge, United States.
Bilayer Therapeutics operates in Biotechnology, Health Care, Health and Wellness and Life Sciences. Its work centres on GI disease, metabolic disorders, obesity and diabetes.
Bilayer Therapeutics has approximately 1 employees.
Bilayer Therapeutics has completed 1 funding round, raising a total of $2.00M. The latest funding stage is Venture round.
Top alternatives and competitors to Bilayer Therapeutics include Movetis NV, Intercept Pharmaceuticals, Xeno Biosciences, DiObex, Mestag Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Bilayer Therapeutics and Movetis NV are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Bilayer Therapeutics, https://bouncewatch.com/company/bilayer-therapeutics, updated 10 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout